Discovery & Development Europe 2026
Estrel Congress Centre, Berlin, Germany
We are excited to announce that Ravi Kiran, Chief Scientific Officer of Vigilare BP, will attend Discovery & Development Europe 2026, one of the most influential gatherings on the pharmaceutical and life sciences calendar, organized by Oxford Global.
The event brings together 1,000+ senior leaders from pharma, biotech, academia, and technology organizations across two co-located programs over two full days of science, collaboration, and discovery.
This year’s edition spans three major tracks:
- Drug Discovery Europe, exploring how AI, advanced biology, and translational science are reshaping early-stage pipeline decisions, from target identification and computational chemistry to ADC development, lab automation, and neuroscience drug development.
- Formulation & Delivery Europe, covering drug product design, delivery science, biologics formulation, RNA and oligonucleotide delivery, and analytical development.
- Neuroscience Drug Development Europe, advancing neuroscience through models, biomarkers, and data-driven discovery across neurodegeneration, neuroinflammation, and translational science.
Chief Scientific Officer, Vigilare BP
Why Ravi Kiran Is Attending
As Chief Scientific Officer, Ravi Kiran will be at the forefront of conversations shaping the next generation of drug discovery and development. The event presents an opportunity to engage with world-class scientists and R&D leaders.
Key areas of focus during the event will include:
- The role of AI and machine learning in accelerating target identification and drug design
- Advances in formulation and delivery for next-generation biotherapeutics
- Collaboration strategies to overcome pipeline failure rates and improve clinical success
- Innovations in neuroscience drug development, including novel biomarkers and disease modeling
- The intersection of lab automation, data systems, and early-stage R&D efficiency
Comments are closed